Aldeyra Therapeutics Inc 2025年季度报告

For the quarterly period endedMarch 31,2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromto.Commission File Number:001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware(State or Other Jurisdiction ofIncorporation or Organization) 131 Hartwell Avenue,Suite 320Lexington,MA(Address of principal executive offices) 02421(Zip Code) (781)761-4904(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smallerreporting company or an emerging growth company. See the definitions of the “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 12, 2025, there were59,895,588shares of the registrant’s common stock issued and outstanding. Aldeyra Therapeutics, Inc. Quarterly Report on Form 10-QFor the Quarter Ended March 31, 2025 INDEX PART I – FINANCIAL INFORMATIONITEM 1.Condensed Consolidated Financial Statements: 3Consolidated Balance Sheets at March 31, 2025 (Unaudited) and December 31, 20243Consolidated Statements of Operations for the three months ended March 31, 2025 and 2024 (Unaudited)4Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2025 and 2024(Unaudited)5Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2025 and 2024(Unaudited)6Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024 (Unaudited)7Notes to Condensed Consolidated Financial Statements (unaudited)8ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20ITEM 3.Quantitative and Qualitative Disclosures about Market Risk29ITEM 4.Controls and Procedures29 ITEM 1.Legal ProceedingsITEM 1A.Risk FactorsITEM 2.Unregistered Sales of Equity Securities and Use of ProceedsITEM 3.Defaults Upon Senior SecuritiesITEM 4.Mine Safety DisclosuresITEM 5.Other InformationITEM 6.ExhibitsSignatures Item 1.Condensed Consolidated Financial Statements. ALDEYRA THERAPEUTICS, INC. CONSOLIDATED BALANCESHEETS ALDEYRA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) ALDEYRA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. ALDEYRA THERAPEUTICS, INC. ALDEYRA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF CASHFLOWS (Unaudited) ALDEYRA THERAPEUTICS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 1.NATURE OF BUSINESS Aldeyra Therapeutics, Inc., together with its wholly owned subsidiaries (the “Company” or “Aldeyra”), a Delawarecorporation, is a clinical-stage biotechnology company devoted to discovering and developing innovative therapies designed totreat immune-mediated and metabolic diseases. The principal activities of the Company to date include research and development activities along with related general businessplanning, including raising capital. 2.BASIS OF PRESENTATION The accompanying interim condensed consolidated financial statements and related disclosures are unaudited and have beenprepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and theinstructions to Form 10-Q and Regulation S-X. Accordingly, the interim condensed consolidated financial statements do notinclude all the information and footnotes required by GAAP for complete financial statements and should be read inconjunction with the audited consolidated fina